• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Advanced Development Center (ADC) for Vaccine Programs in Massachusetts

    6/16/22 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TNXP alert in real time by email

    The ADC is Expected to Accelerate Clinical-Scale Manufacturing of Live Virus Vaccines, Including Vaccines for Monkeypox, Smallpox and COVID-19

    Internal Manufacturing Capabilities Expected to Support U.S. Pandemic Preparedness

    CHATHAM, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will hold a ribbon-cutting ceremony at the Company's 45,000 square foot clinical-scale manufacturing facility in the New Bedford Business Park in North Dartmouth, Massachusetts on June 21, 2022 at 1:00 pm ET. The new facility houses Tonix's Advanced Development Center (ADC) for accelerated research, development and analytical capabilities, as well as the production of clinical trial quality vaccines for infectious diseases, including monkeypox, smallpox and COVID-19 as well as other infectious diseases for pandemic preparedness. The ceremony marks the formal opening of the New Bedford site.

    U.S. Representative Bill Keating; the mayor of New Bedford, Mass., Jon Mitchell; Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals; and other prominent community members and employees plan to attend the event.

    The ADC includes single-use bioreactors and purification suites with equipment for Good Manufacturing Practice (GMP) production of vaccines for clinical trials, including the capability of producing sterile vaccines in glass bottles. The ADC is Biosafety Level 2 (BSL-2). At full capacity, the facility can employ up to 70 researchers, scientists, manufacturing and technical support staff.

    "Tonix Pharmaceuticals is making good on their promise to bring jobs to the New Bedford area, and we should be proud to host this new facility that has the potential to impact lives all over the world," said Congressman Bill Keating. "Thanks to the hard work of Tonix, the town of Dartmouth and City of New Bedford, this facility opening further cements the role that the South Coast is playing in biotech. The continued private and public sector investments in our region are paying dividends, and the ribbon-cutting for this facility serves as yet another positive indicator of continued economic growth on the South Coast."

    "The addition of Tonix Pharmaceuticals to the growing biotech community in Greater New Bedford is a strong indicator of the quality of the region's workforce. We have the talent to compete in a variety of sectors," said Jon Mitchell, Mayor of the City of New Bedford.

    "The opening of our new manufacturing facility in the New Bedford Business Park is a significant milestone for Tonix and we are excited to be part of the growing biotech industry in the South Coast region of Massachusetts," stated Dr. Lederman. "The ADC greatly enhances our ability to progress our pipeline of vaccines for infectious diseases, including monkeypox, smallpox and COVID-19. We believe that the recombinant pox virus platform technology underlying our key vaccines in development, TNX-801, TNX-1840 and TNX-1850, coupled with our capabilities at the Tonix R&D Center (RDC) for research and development, will be rapidly deployable for addressing potential novel or emerging pathogens, with simplified distribution and administration, relative to modified mRNA-based vaccines. Our goal is to be able to design and test new recombinant pox virus vaccines against novel pathogens within the 100 days of recognition of a potential emerging pandemic threat, consistent with the criteria set forth by the White House Office of Science and Technology Policy. With high quality people, systems and processes, we intend to be a center of excellence for vaccine development."

    The facility is located in the New Bedford Business Park in a section of the park that is located in the Town of Dartmouth, Massachusetts. The two municipalities work together to accommodate businesses located in the Dartmouth portion of the park as the roads are inaccessible through Dartmouth and municipal services are provided by the City of New Bedford.

    Tonix Pharmaceuticals Holding Corp.1

    Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix's CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the first quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication that Phase 2 ready and has been granted Breakthrough Therapy Designation by the FDA. TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the second half of 2022. Tonix's rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix's infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox called TNX-801, next-generation vaccines to prevent COVID-19, and a platform to make fully human monoclonal antibodies to treat COVID-19. Tonix's lead vaccine candidates for COVID-19 are TNX-1840 and TNX-1850, which are live virus vaccines based on Tonix's recombinant pox live virus vector vaccine platform.

    1All of Tonix's product candidates are investigational new drugs or biologics and have not been approved for any indication.

    This press release and further information about Tonix can be found at www.tonixpharma.com.

    Forward Looking Statements

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the "SEC") on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

    Contacts

    Jessica Morris (corporate)

    Tonix Pharmaceuticals

    [email protected]

    (862) 904-8182

    Olipriya Das, Ph.D. (media)

    Russo Partners

    [email protected]

    (646) 942-5588

    Peter Vozzo (investors)

    Westwicke/ICR

    [email protected]

    (443) 213-0505



    Primary Logo

    Get the next $TNXP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TNXP

    DatePrice TargetRatingAnalyst
    4/18/2022Outperform
    Noble Capital Markets
    More analyst ratings

    $TNXP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

      Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells TNX-1700 is in preclinical development for gastric and colorectal cancers CHATHAM, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented data in a poster presentation at the American Association for Cancer Research (AACR) 2025 Annual Meeting, held April 25-30, 2025, in Chicago, IL. A copy of the Company's presentation is available under the Scient

      4/29/25 9:05:04 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

      TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virus Durability of TNX-801 vaccination shown by six-month protection of animals from a lethal challenge with rabbitpox Tolerability of TNX-801 demonstrated in immunocompromised animals by no spreading to blood or tissues, even at high doses CHATHAM, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented data in an

      4/24/25 7:55:30 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025

      CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company will deliver an oral presentation and lead a panel discussion at the World Vaccine Congress Washington 2025, which will be held in Washington, D.C., April 22-24, 2025. A copy of the Company's presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the World Vaccine Congress website here. Presentati

      4/16/25 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Tonix Pharma

      Noble Capital Markets initiated coverage of Tonix Pharma with a rating of Outperform

      4/18/22 9:20:45 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners resumed coverage on Tonix Pharmaceuticals with a new price target

      Alliance Global Partners resumed coverage of Tonix Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $3.00 previously

      2/25/21 7:39:46 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bell Margaret Smith disposed of $0 worth of shares (1 units at $0.15), closing all direct ownership in the company (SEC Form 4)

      4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

      2/28/25 5:32:22 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Treco James disposed of $0 worth of shares (0 units at $0.30), closing all direct ownership in the company (SEC Form 4)

      4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

      2/28/25 5:31:48 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Olukotun Adeoye Y disposed of $2 worth of shares (1 units at $1.91), closing all direct ownership in the company (SEC Form 4)

      4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

      2/28/25 5:31:25 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Financials

    Live finance-specific insights

    See more
    • Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products

      Strategic Acquisition Helps Build Tonix's Commercial Capabilities and Infrastructure Ahead of Potential Launch of TNX-102 SL for the Management of Fibromyalgia Acquisition of Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray), Indicated for the Treatment of Acute Migraine in Adults, Complements Tonix's Current Intranasal Clinical Development Program of TNX-1900 for Migraine Prevention CHATHAM, N.J., July 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix Pharmaceuticals or Tonix), a biopharmaceutical company, and its wholly-owned commercialization subsidiary Tonix Medicines, Inc. (Tonix Medicines), today announced it

      7/3/23 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights

      Five Potentially Pivotal Phase 2 or 3 Studies for CNS Programs Expected to be in the Clinic by First Quarter 2023 Data from Planned Interim Analyses of TNX-102 SL in Phase 3 Fibromyalgia Study and Phase 2 Long COVID Study Expected Second Quarter 2023 Advanced Development Center in Dartmouth, Mass. and Infectious Disease Research and Development Facility in Frederick, Md. Operational Cash and Cash Equivalents Totaled Approximately $140 Million at September 30, 2022 CHATHAM, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the

      11/7/22 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Advanced Development Center (ADC) for Vaccine Programs in Massachusetts

      The ADC is Expected to Accelerate Clinical-Scale Manufacturing of Live Virus Vaccines, Including Vaccines for Monkeypox, Smallpox and COVID-19 Internal Manufacturing Capabilities Expected to Support U.S. Pandemic Preparedness CHATHAM, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will hold a ribbon-cutting ceremony at the Company's 45,000 square foot clinical-scale manufacturing facility in the New Bedford Business Park in North Dartmouth, Massachusetts on June 21, 2022 at 1:00 pm ET. The new facility houses Tonix's Advanced Development Center (ADC) for acce

      6/16/22 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    SEC Filings

    See more
    • SEC Form 8-K filed by Tonix Pharmaceuticals Holding Corp.

      8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

      5/8/25 5:16:06 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

      4/29/25 4:08:13 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events

      8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

      4/25/25 4:59:30 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      11/14/24 4:42:22 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      11/14/24 4:40:17 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      10/16/24 9:01:20 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Leadership Updates

    Live Leadership Updates

    See more
    • Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth quarter 2025 launch of TNX-102 SL for fibromyalgia; $98.8 million in cash as of December 31, 2024 Announced positive topline results from Phase 1 study of TNX-1500, a next generation anti-CD40L mAb candidate for prevention of kidney transplant rejection and treatment of autoimmune diseases Received government grant for potential mpox vaccine, TNX-801, which has demonst

      3/18/25 4:30:00 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access

      Mr. Ainsworth brings over two decades of industry and market access experience to Tonix U.S. Food and Drug Administration (FDA) recently assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for U.S. marketing authorization of TNX-102 SL for the management of fibromyalgia CHATHAM, N.J., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the appointment of Gary Ainsworth as Vice President, Market Access, effective immediately. Mr. Ainsworth is an accomplished executive with leadershi

      1/8/25 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires

      Tonix appoints two executives with decades of experience successfully launching and commercializing new CNS products Bradley Raudabaugh, MBA, joins as Vice President, Marketing, bringing over 25 years of marketing, sales and product planning experience to Tonix Errol Gould, Ph.D., joins Tonix as Vice President, Medical Affairs, with over 25 years of experience in R&D and medical affairs across a wide range of therapeutic areas, including fibromyalgia New Drug Application (NDA) for TNX-102 SL for the management of fibromyalgia submitted to FDA in October 2024; NDA acceptance expected December 2024; Fast Track designation previously granted by FDA; FDA decision on approval expected 2025 If

      12/3/24 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care